Sipai Health Technology (0314) H1 2025 earnings summary

Executive summary

• Strategic pivot toward commercial health insurance and an integrated medical, pharmacy, wellness and insurance network; restructuring lifted gross margin and narrowed normalized net loss.

• Specialty Pharmacy restructuring drove a sharp revenue decline, while Enterprise Health Insurance expanded.

Financial highlights

• H1 revenue was RMB1,224.1m, down 48.2% YoY; gross profit was RMB176.1m, down 23.1%.

• IFRS net loss was RMB81.1m versus RMB74.7m; normalized net loss fell 59.6% to RMB12.0m, while operating loss narrowed 29.6% to RMB60.4m.

• Selling and marketing expenses fell 41.3% to RMB80.9m, administrative expenses fell 7.0% to RMB150.5m, and R&D expenses fell 66.1% to RMB5.1m.

• Adjusted loss was RMB24.8m; the measure excludes specified non-recurring and non-operational items.

Outlook and guidance

• Management expected continued growth and improving profitability in H2 2025 and beyond, supported by policy tailwinds, data assets and AI-led capabilities; no quantified guidance was stated.

• Priorities include scaling commercial health insurance, expanding service networks, accelerating digital transformation, improving efficiency and customer experience, and strengthening cash flow.